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Generalized anxiety disorder (GAD) is associated with painful physical symptoms (PPS). 
These post hoc analyses of previous trial data assessed PPS and their response to duloxetine 
treatment in GAD patients. Studies 1 and 2 (n = 840) were 9- to 10-week efficacy trials; study 
3 (n = 887) was a relapse prevention trial comprising a 26-week open-label treatment phase 
and a 26-week double-blind, placebo-controlled treatment continuation phase. Mean baseline 
visual analog scale scores (VAS, 0–100; n = 1727) ranged from 26 to 37 for overall pain, 
headache, back pain, shoulder pain, interference with daily activities, and time in pain while 
awake. In studies 1 and 2, improvement on all VAS scores was greater in duloxetinetreated 
than in placebo-treated patients (p ≤ 0.01). In study 3, pain symptoms worsened in responders 
switched to placebo compared with those maintained on duloxetine (p ≤ 0.02). In conclusion, 
duloxetine was efficacious in the short- and long-term treatment of PPS, which are common 
in GAD patients.   
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1. Background  
 
Generalized anxiety disorder (GAD) is a common condition in the general population (12-
month prevalence, 2–3%; lifetime prevalence, 5–6%) (Beesdo, Pine, Lieb, & Wittchen, in 
press; Lieb, Becker, & Altamura, 2005; Ruscio et al., 2007; Wittchen, Zhao, Kessler, & 
Eaton, 1994) and ranks among the most frequently encountered mental disorders in primary 
care (Stein, 2003), with point prevalence rates of up to 14.8% (Ansseau et al., 2004; Olfson et 
al., 2000; Wittchen, Kessler et al., 2002). Primary care studies have also shown that GAD 
patients frequently remain undiagnosed or are misdiagnosed and poorly treated, which may be 
due to the fact that only 13% of GAD patients initially report anxiety symptoms as their 
reason for help seeking (Wittchen, Kessler et al., 2002). More often, they complain of a range 
of somatic problems, with pain being among the most frequent (35%) presenting symptoms. 
Because of the nature of GAD symptoms and its typically chronic course, GAD is associated 
with considerable burden in terms of impaired occupational, family, and social functioning, as 
well as high utilization of health care resources (Kessler, DuPont, Berglund, & Wittchen, 
1999; Olfson & Gameroff, 2007; Wittchen, Beesdo, & Kessler, 2002; Wittchen, Carter, 
Pfister, Montgomery, & Kessler, 2000; Wittchen, Kessler et al., 2002).  
 
Epidemiological data both from primary care (Means-Christensen, Roy-Byrne, Sherbourne, 
Craske, & Stein, 2008; Olfson & Gameroff, 2007) and from the general population (Beesdo, 
Jacobi et al., 2009; Demyttenaere et al., 2007; Fröhlich, Jacobi, &Wittchen, 2006; Gureje et 
al., 2008; McWilliams, Cox, & Enns, 2003; McWilliams, Goodwin, & Cox, 2004) confirm 
that painful physical symptoms are commonly associated with GAD. More recent evidence 
suggests that the association of pain and GAD is substantial, and that pain is a specific feature 
of GAD that is not seen at the same frequency or intensity in other anxiety disorders (Beesdo, 
Hoyer et al., 2009). Because of the high rates of comorbid GAD and pain and the 
demonstration that this pattern is associated with more adverse negative outcomes, such as 
higher disability, decreased quality of life, and increased service utilization, than either 
condition individually (Beesdo, Hoyer et al., 2009), there is need for optimized treatment 
strategies for patients suffering from GAD and pain.  
 
Duloxetine is a selective dual reuptake inhibitor of serotonin and norepinephrine (Wong & 
Bymaster, 2002), which has been shown to be efficacious, safe, and well tolerated in the 
treatment of GAD (Davidson et al., 2008; Hartford et al., 2007; Koponen et al., 2007; Rynn et 
al., 2008). Clinical studies have also provided evidence for the efficacy of duloxetine for pain 
conditions. In the US, duloxetine is approved for the management of diabetic peripheral 
neuropathic pain (DPNP) (Goldstein, Lu, Detke, Lee, & Iyengar, 2005; Raskin et al., 2005) 
and reducing pain associated with fibromyalgia (Arnold et al., 2004, 2005; Russell, Mease et 
al., 2008). In addition, duloxetine has been shown to reduce painful physical symptoms 
associated with depression (Goldstein et al., 2004). In more recent clinical studies, duloxetine 
was also found to effectively reduce somatic symptoms and pain severity in patients with 
GAD (Hartford et al., 2008; Nicolini et al., 2008; Russell, Weisberg et al., 2008). Because 
previous analyses were based on the subgroup of patients who had clinically significant pain 
levels (visual analogue scale [VAS] scores ≥ 30 at baseline) (Hartford et al., 2008; Russell, 
Weisberg et al., 2008), additional investigation of the effect of duloxetine on painful physical 
symptoms in GAD patients from the overall clinical trial population would be informative to 
describe the presence and course of painful physical symptoms in patients with GAD.  
 
The present study further investigates previous findings through a post hoc analysis of data 
from three independent clinical studies from the duloxetine clinical trial program. The 
objective of these analyses was to provide a more detailed and sufficiently powered 
examination of the frequency, clinical presentation, and course of painful physical symptoms 
in GAD patients. The analyses also aimed to provide data on the response of painful physical 
symptoms to short- and long-term treatment with duloxetine in patients with GAD.  
 
2. Methods  
 
2.1. Overview  
 
Data were included in the analyses from two short-term, multicenter, randomized, double-
blind, placebo-controlled, phase 3 trials and one long-term, multicenter, randomized, double-
blind, placebo-controlled, phase 3 relapse prevention trial of the efficacy and safety of 
duloxetine in patients with a principal diagnosis of GAD. In all three studies, ethical review 
boards provided approval of the study protocols in accordance with the principles of the 
Declaration of Helsinki, and all patients provided written informed consent.  
 
Studies 1 and 2 each consisted of a 1-week, single-blind, placebo lead-in phase; a 9-week 
fixed-dose (study 1) or 10-week flexible-dose (study 2) double-blind treatment phase; and a 2- 
week discontinuation phase. Patients in study 1 received duloxetine 60 mg once daily, 
duloxetine 120 mg once daily, or placebo. Patients in study 2 received duloxetine 60–120 mg 
once daily, according to the investigator’s judgment and patient tolerance, or placebo. A total 
of 840 patients were randomly assigned to treatment in these two studies; of these, 780 had 
postbaseline VAS measures for pain variables. These studies are described in detail in 
previous publications (Koponen et al., 2007; Rynn et al., 2008).  
 
Study 3 was a long-term relapse prevention study comprised of a 26-week open-label, 
flexible-dose treatment phase during which all patients received duloxetine; a 26-week 
double-blind, placebo-controlled treatment continuation phase; and a 3-week taper/ follow-up 
therapy phase. In the open-label phase, patients received 60–120 mg once daily according to 
the physician’s judgment and patient tolerance. At the end of the open-label phase, patients 
who met the response criteria (responders) were randomized to receive either duloxetine 
(maintained at the same dose as received during the open-label phase), or placebo for 26 
weeks. Response was defined as a decrease from the baseline Hamilton Anxiety Rating Scale 
(HAMA) total score of at least 50% to a score no higher than 11 and a Clinical Global 
Impressions of Improvement (CGI-Improvement) score of 1 or 2 for the last two consecutive 
visits prior to randomization. A total of 887 patients were randomly assigned to treatment in 
study 3. Of these, 739 had post-baseline VAS pain measures during the open-label phase, and 
392 responded to treatment in the open-label phase and had post-baseline VAS measurements 
during the placebo-controlled treatment continuation phase. This study is described in detail 
in a previous publication (Davidson et al., 2008).  
 
2.2. Patients  
 
In all three studies, eligible patients were at least 18 years old and met the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition (DSM-IV), criteria for GAD. Diagnosis 
was determined on the basis of the Mini International Neuropsychiatric Interview (MINI) 
(Sheehan et al., 1998) and was confirmed by a psychiatrist. GAD had to be at least moderately 
severe as indicated by a rating of ≥4 (moderate) on the Clinical Global Impressions of 
Severity (CGIS) Scale (Guy, 1976), a Hospital Anxiety and Depression Scale (HADS) 
anxiety subscale score of ≥10 (Zigmond & Snaith, 1983), and a Covi Anxiety Scale (CAS) 
score of ≥9 (Lipman & Covi, 1976). To ensure predominance of anxiety symptoms, none of 
the five items on the Raskin Depression Rating (RDR) scale (Raskin et al., 1969) could be 
scored >3 and the CAS score had to be greater than the RDR total.  
 
Patients were excluded if they had a recent (past 6 months) diagnosis of major depressive 
disorder or substance abuse or dependence; a history in the past year of panic disorder, 
posttraumatic stress disorder, or eating disorder; or a lifetime history of obsessive compulsive 
disorder, bipolar affective disorder, psychosis, factitious disorder, or somatoform disorders. 
Patients were required not to take excluded medications within predefined periods before the 
start of the placebo lead-in phase (studies 1 and 2) or the open-label phase (study 3) of the 
studies. Patients were also excluded if they had any medical condition that would 
contraindicate the use of duloxetine and if their GAD had not responded to two or more 
adequate trials of pharmacological treatment. Detailed descriptions of the inclusion and 
exclusion criteria applied in these studies have been published previously (Davidson et al., 
2008; Koponen et al., 2007; Rynn et al., 2008).  
 
 
2.3. Pain measures—visual analogue scale (VAS)  
 
In all three studies, patients rated their pain using six visual analog scales (DeLoach et al., 
1998). Each scale consisted of a 100- mm line anchored on the ends by 0 or 100. Patients used 
separate scales to rate overall pain, shoulder pain, back pain, and headache from 0 (none) to 
100 (as severe as I can imagine); time during the day in pain from 0 (none of the time) to 100 
(all of the time); and interference with activities due to pain from 0 (not at all) to 100 
(complete disability).  
 
2.4. Statistical methods  
 
Baseline data from studies 1, 2, and 3 were pooled and descriptive statistics, including mean, 
median, standard deviation, and 25th and 75th percentiles, were calculated to provide a profile 
of the presentation of painful physical symptoms at baseline.  
 
The short-term response to treatment was assessed on the basis of pooled data from the 
duloxetine and placebo arms of studies 1 and 2. Differences in VAS scores between the 
treatment arms in the changes from baseline to endpoint were examined with an analysis of 
covariance (ANCOVA) model that included treatment and study as main effects and baseline 
VAS score as the covariate. Changes from baseline in pain scores by treatment group and 
remission (HAMA total score ≤7 at endpoint) and response (≥50% reduction from baseline in 
HAMA total score) status were examined using ANCOVA.   
 
The long-term response to treatment was assessed on the basis of data from the placebo-
controlled treatment continuation phase of study 3. Changes from baseline to endpoint in 
VAS scores during the 26-week open-label treatment phase were compared with zero to 
determine if within-treatment change was significant. Differences between the treatment 
groups in the changes in VAS scores from the baseline of the 26-week placebo-controlled 
treatment continuation phase to the study endpoint were examined with an ANCOVA model 
that included treatment and investigator as main effects and baseline VAS score at 
randomization as a covariate. In analyses similar to those performed for studies 1 and 2, 
changes from baseline in pain scores by treatment group and remission and response status 
were examined in the open-label acute therapy phase using ANCOVA.  
 
Differences between the treatment groups in the changes in VAS scores from baseline were 
also examined by relapse status in the placebo-controlled treatment continuation phase with 
an ANCOVA model that included treatment as a main effect and baseline VAS score at 
randomization as a covariate. Relapse was defined as an increase from randomization in CGI-
S score of at least 2 points to a score greater than or equal to 4, a MINI diagnosis of GAD 
(excluding the requirement for duration of 6 months), or discontinuation due to lack of 
efficacy. The changes in VAS scores from baseline to endpoint in the open-label treatment 
phase were examined by relapse status in the placebo-controlled treatment continuation phase 
with the same ANCOVA model.  
 
Effect sizes were calculated for changes from baseline in mean VAS pain scores in combined 
data from studies 1 and 2, and in the placebo-controlled continuation phase of study 3 
according to the methods described by Hedges and Olkin (1985).  
 
All analyses used last observation carried forward (LOCF) to handle missing data or drop outs 
and the intent to treat sample (ITT), which is defined as patients who were randomly assigned 
to a treatment, even if they deviated from the protocol or course of treatment.  
 3. Results  
 
3.1. Baseline patient demographics and presentation of painful physical symptoms  
 
Within studies 1 and 2, the treatment groups were similar with respect to baseline 
demographic characteristics (p ≥ 0.239; Table 1). In the sample of pooled data from studies 1, 
2, and 3 (n = 1727), the mean (standard deviation) baseline VAS scores were 32.9 (25.5) for 
overall pain, 26.7 (27.0) for headache, 28.5 (27.9) for back pain, 26.6 (28.6) for shoulder pain, 
27.5 (26.9) for interference with daily activities, and 37.1 (30.5) for time in pain while awake. 
Given the large standard deviations, baseline median values for VAS scores were also 
examined. At least 50% of the patients had scores ≥28 for overall pain, ≥19 for headache, ≥20 
for back pain, ≥15 for shoulder pain, ≥18 for pain interference with daily activities, and ≥31 
for pain while awake.  
 
3.2. Short-term response to treatment  
 
3.2.1. Overall  
In studies 1 and 2, the placebo and duloxetine groups were similar at baseline with respect to 
all six VAS pain scores (p ≥ 0.088). In these studies, improvement from baseline on all VAS 
pain scores was significantly greater in duloxetine-treated patients than in placebo-treated 
patients (p ≤ 0.01 to ≤0.001; Fig. 1). On average, duloxetine-treated patients experienced 
significant reductions from baseline of at least 30% in each of the pain scales assessed (p ≤ 
0.001). The effect sizes for duloxetine for the changes from baseline in the six VAS pain 
measures ranged from 0.15 to 0.21.  
 
The findings during the 26-week, open-label treatment phase of study 3 were consistent with 
and supported those in studies 1 and 2. The mean VAS scores at endpoint were significantly 
lower than those at baseline for all six pain scales, reflecting improvement in pain symptoms 
during open-label duloxetine treatment (each p ≤ 0.001). On average, these patients 
experienced reductions in baseline pain scale scores of at least 34% on each pain scale.  
 
3.2.2. Comparison of pain outcomes by treatment group and remission and response status  
Changes from baseline in pain scores were assessed in patients in the two treatment groups in 
studies 1 and 2 on the basis of GAD remission status (remitters and nonremitters) and on the 
basis of response status (responders and nonresponders) (Table 2). In both treatment groups, 
the changes from baseline in all pain measures were numerically greater in remitters and 
responders than in nonremitters and nonresponders. Among remitters and responders, the 
changes from baseline in pain scores did not differ significantly between the placebo and 
duloxetine groups. In contrast, among nonremitters and nonresponders, the improvement from 
baseline in overall pain was significantly greater in the duloxetine group than in the placebo 
group. This pattern was noted for all pain variables except for headache among nonremitters 
and nonresponders and interference with daily activities and pain while awake among 
nonresponders.  
 
Changes from baseline in pain scores were also assessed in patients in study 3 who did and 
did not achieve remission and those who did and did not achieve response during open-label 
treatment with duloxetine. As in studies 1 and 2, changes from baseline in all pain measures 
were numerically greater in remitters and responders than in nonremitters and nonresponders 
(Table 3). Both remitters and nonremitters as well as responders had significant changes from 
baseline in all pain measures whereas nonresponders did not.  
 3.3. Long-term response to treatment  
 
3.3.1. Overall  
In study 3, the placebo and duloxetine groups were similar with respect to all six VAS pain 
scores at the baseline of the 26-week placebo-controlled treatment continuation phase (p ≥ 
0.181). The study design allows comparison of the specific long-term effects between 
responders who either continued duloxetine treatment or were randomized to placebo. During 
this phase, responders randomized to placebo experienced least-squares mean increases in 
pain scale scores ranging from 5.2 to 8.7, whereas those who continued duloxetine treatment 
experienced only slight fluctuations in their pain scores, ranging from -1.6 to 0.6 (Fig. 2). The 
differences in the least-squares mean changes in VAS pain scores between the duloxetine- and 
placebo-treated patients during this phase were significant for each of the six pain scales (p ≤ 
0.02 to p ≤ 0.001; Fig. 2). On average, patients in the placebo group had increases from the 
baseline of the placebo-controlled phase in pain scale scores of 32–62%. In contrast, mean 
changes from baseline in the pain scores for patients in the duloxetine group ranged between -
6% and 7% of baseline scores. Effect sizes for duloxetine for the changes in the six VAS pain 
measures after long-term treatment ranged from 0.17 to 0.38.  
 
3.3.2. Comparison of pain outcomes in patients who relapsed and those who did not  
The changes in pain scores during the placebo-controlled treatment continuation phase of 
study 3 were compared between responders who relapsed during this phase (relapsers) and 
those who did not (nonrelapsers). Overall, patients who relapsed showed greater worsening in 
pain symptoms than nonrelapsers (Fig. 3). In nonrelapsers, pain scores continued to decrease 
among duloxetine- treated patients and to increase among placebo-treated patients. 
Differences in these changes between the placebo and duloxetine groups were significant for 
overall pain (p = 0.002) and shoulder pain (p = 0.009). In relapsers, pain scores increased in 
both treatment groups, and the increases were numerically greater in the placebo group than in 
the duloxetine group for four of the six measures, although the differences were not 
significant (Fig. 3). In both treatment groups, there was a trend for pain scores at the baseline 
of the placebo-controlled treatment continuation phase to be higher in relapsers (range, 13.5–
23.2 in the placebo group; 19.6–28.4 in the duloxetine group) than in nonrelapsers (9.4–14.8 
in the placebo group; 9.8–14.2 in the duloxetine group). Examination of changes from 
baseline in pain scores during the open-label treatment phase of the study showed that 
responders who did not relapse during the continuation phase had experienced a significantly 
greater reduction in pain during the open-label therapy phase than relapsers (Table 4).  
 
4. Discussion  
 
The results of these post hoc analyses from three duloxetine trials yielded three principal 
findings. First, painful physical symptoms in these patients were part of the clinical 
presentation of GAD and varied widely in severity. Second, duloxetine was significantly more 
effective than placebo in reducing painful physical symptoms of GAD after short-term 
treatment. And third, patients who discontinued duloxetine treatment experienced a worsening 
of their painful physical symptoms, whereas patients who continued duloxetine treatment did 
not. Worsening of painful physical symptoms tended to be greater in patients who had relapse 
of their GAD symptoms. Similarly, improvement in painful physical symptoms tended to be 
less among patients who did not achieve remission or a response in their GAD symptoms than 
in those who did.  
 
The patients entered in these trials had a principal diagnosis of DSM-IV GAD of at least 
moderate severity, but were not required to meet a minimum threshold for pain. Nevertheless, 
at study entry, the mean VAS scores for overall pain and time in pain exceeded 30 and were 
therefore indicative of clinically significant pain (Collins, Moore, McQuay, 1997). This study 
differs from previous analyses in that patients were not selected on the basis of pain at 
baseline (Hartford et al., 2008; Russell, Weisberg et al., 2008); the findings in this large 
general clinical population of patients with GAD suggest that painful physical symptoms are 
common in GAD and are relevant as a part of this disease state.  
 
Our findings that painful physical symptoms are commonly associated with GAD are 
consistent with data from epidemiological studies (Beesdo, Hoyer et al., 2009; Demyttenaere 
et al., 2007; Gureje et al., 2008; McWilliams et al., 2003; McWilliams et al., 2004; Von Korff 
et al., 2005). These studies provide evidence that, among the anxiety disorders, GAD appears 
to be particularly strongly related to pain (Beesdo, Hoyer et al., 2009; Demyttenaere et al., 
2007; Von Korff et al., 2005) and that the presence of GAD is generally associated with pain 
symptoms in multiple body sites (Gureje et al., 2008; McWilliams et al., 2004). There are also 
indications that GAD-pain link persists even when adjustments are made for the presence of 
factors that may contribute to this association, such as demographics and comorbidities 
(Beesdo, Hoyer et al., 2009; McWilliams et al., 2004; Means-Christensen et al., 2008). In 
both the pooled analyses of data from studies 1 and 2 and analysis of data from the open-label 
phase of study 3, duloxetine treatment was associated with clinically significant reductions in 
pain (Farrar et al., 2001). Effect sizes ranged from 0.15 to 0.21 after short-term treatment 
(studies 1 and 2) and from 0.17 to 0.38 after long-term treatment (study 3). Turner, Matthews, 
Linardatos, Tell, and Rosenthal (2008) showed that for positive neuroscience studies which 
contribute to successful regulatory submissions across 74 Food and Drug Administration 
(FDA)- registered studies, the average effect size was 0.33; across 12 approved antidepressant 
agents, the average effect size was 0.31 (Turner et al., 2008). Given that the patients included 
in our analyses were not selected for the presence or severity of pain symptoms, the effect 
sizes observed are considerable, particularly those for long-term treatment.  
 
In study 3, as reported previously, patients who responded to duloxetine treatment and were 
subsequently switched to placebo treatment were significantly more likely to experience 
relapse of anxiety symptoms of GAD than patients who continued duloxetine treatment 
(41.8% vs. 13.7%; p ≤ 0.001) (Davidson et al., 2008). The current analyses revealed that 
patients who discontinued duloxetine treatment also experienced a worsening of their painful 
physical symptoms, whereas patients who continued duloxetine treatment maintained their 
improvements. These findings suggest that painful physical symptoms may reoccur with 
relapse of GAD and that continuation of duloxetine treatment after abatement of symptoms 
continues to protect patients from relapse of painful physical symptoms.  
 
Indeed, our comparison of patients who had GAD relapse with those who did not revealed 
that painful physical symptoms worsened to a greater extent in GAD relapsers than in 
nonrelapsers. These analyses also showed that among both relapsers and nonrelapsers, 
duloxetine-treated patients tended to have lower pain severity than placebo-treated patients, 
particularly among nonrelapsers. Our finding that relapsers tended to have a better response to 
duloxetine than to placebo on most pain scales supports a previous finding that suggested that 
duloxetine’s effect on pain is at least in part independent of changes in anxiety symptoms 
(Russell, Weisberg et al., 2008). These findings, combined with our observation that some 
GAD nonrelapsers experienced worsening of their pain symptoms, especially when switched 
to placebo, suggest that painful physical symptoms may be somewhat independent of other 
core anxiety symptoms in GAD. Nevertheless, co-occurring painful physical symptoms 
should be carefully considered in the management of GAD patients. Comparison of the pain 
response to duloxetine during open-label treatment between GAD relapsers and nonrelapsers 
showed that nonrelapsers had a significantly greater reduction in their pain symptoms during 
open-label treatment than relapsers. These findings suggest that better pain management may 
be associated with sustained GAD treatment response.  
 
The results of comparisons of pain outcomes in remitters and nonremitters and responders and 
nonresponders showed that patients who achieved remission or response in their GAD 
symptoms tended to have greater improvement in pain measures than those who did not. 
These analyses also showed that among nonremitters and nonresponders in studies 1 and 2, 
improvement in pain symptoms were significantly greater in duloxetine- than placebo-treated 
patients, suggesting that duloxetine treatment is associated with improvement in pain 
symptoms even in patients whose GAD symptoms have not responded. This finding supports 
our earlier observation that duloxetine’s effect on pain may be to some degree independent of 
changes in anxiety symptoms.  
 
During the open-label phase of study 3, pain symptoms were significantly improved among 
nonremitters but not among nonresponders. Such discrepancy can be understood when the 
criteria for response and remission are considered. Patients who satisfied response criteria 
may not have satisfied remission criteria; therefore, the group of nonremitters may have 
included some responders who experienced improvement in VAS pain scores. The pain scores 
for these responders would have led to increased values for the change from baseline in pain 
scores for the group of nonremitters. Thus, in study 3, unlike in studies 1 and 2, patients 
whose GAD symptoms did not respond to treatment did not experience a significant 
improvement in their pain symptoms. The difference in the outcomes of these analyses 
between studies 1 and 2 and study 3 may be related to the differences in blinding and duration 
of treatment in these studies. If response in GAD does not occur despite treatment over a 
longer period of time (26 weeks vs. 9/10 weeks), it is also likely that pain symptoms remain 
present over the long run. This patient group may require particular medical attention.  
 
Because of the evidence of increased disability, poorer quality of life, and higher health 
service use in patients with co-occurring GAD and painful physical symptoms compared with 
patients with either condition alone (Beesdo, Hoyer et al., 2009), therapies that effectively 
treat both GAD and pain would be advantageous. The efficacy of duloxetine for the treatment 
of GAD has been demonstrated in five large, double-blind, randomized trials (Davidson et al., 
2008; Hartford et al., 2007; Koponen et al., 2007; Nicolini et al., 2008; Rynn et al., 2008). 
Further, this agent has demonstrated efficacy in animal models of persistent pain (Iyengar et 
al., 2004) and in clinical studies of pain associated with diabetic neuropathy (Goldstein et al., 
2005; Raskin et al., 2005; Wernicke et al., 2006), fibromyalgia (Arnold et al., 2004, 2005; 
Russell, Mease et al., 2008), and depression (Goldstein et al., 2004). The analyses reported 
here demonstrated that patients with GAD who were treated with duloxetine for 9–26 weeks 
experienced on average significant reductions in each of the aspects of painful physical 
symptoms assessed, and patients treated for up to 52 weeks continued to report reduced 
painful physical symptoms throughout the treatment period. Patients who discontinued 
duloxetine treatment, however, experienced a worsening of these symptoms.  
 
The large size of the study population is a strength of these analyses. Nevertheless, several 
limitations may restrict the generalizability of the results. Our findings are based on a post hoc 
analysis of pooled data from three separate clinical trials and cannot be interpreted with the 
same degree of confidence as a prospectively designed study in a randomly selected clinical 
population. Also, all three studies were characterized by a lack of ethnic diversity and 
excluded patients with primary Axis I disorders other than GAD, significant depressive 
symptoms, any lifetime history of psychotic disorder, or serious or unstable medical 
comorbidity. This may limit the ability to generalize these findings to a typical clinical 
population.  
 
In conclusion, results of these analyses indicate that painful physical symptoms are associated 
with the clinical presentation of GAD and vary widely in severity. Both short- and long-term 
duloxetine treatments were associated with improvement in painful physical symptoms in 
GAD. Patients who responded to duloxetine treatment and subsequently discontinued 
treatment experienced a worsening of painful symptoms. These findings suggest that painful 
physical symptoms reoccur with relapsing GAD and indicate a need for ongoing treatment in 
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